Brief: Gensight Biologics: update on parameters of ND4-LHON Subjects before LUMEVOQ® treatment in Phase III Trials

Gensight Biologics SA

09/09/2021 06:35

Sept 9 (Reuters) - Gensight Biologics SA  SIGHT.PA :
    * GENSIGHT BIOLOGICS ANNOUNCES PUBLICATION ANALYZING VISUAL
PARAMETERS OF ND4-LHON SUBJECTS BEFORE LUMEVOQ® TREATMENT IN
PHASE III TRIALS
    * IN FIRST 6 MONTHS POST-VISION LOSS (RESCUE PATIENTS BEFORE
TREATMENT), EACH MONTH AFTER ONSET WAS ASSOCIATED WITH A MEAN
VISUAL ACUITY LOSS OF +0.24 LOGMAR (-12 ETDRS LETTERS
EQUIVALENT)
    * TIME FROM ONSET WAS NOT ASSOCIATED WITH SUBSTANTIAL
WORSENING OF
VISUAL ACUITY FOR PATIENTS BETWEEN 6 AND 12 MONTHS POST-VISION
LOSS (REVERSE PATIENTS BEFORE TREATMENT
    * CROSS-SECTIONAL ANALYSIS REINFORCES KNOWLEDGE OF LHON
NATURAL
HISTORY PROGRESSION: AN ACUTE PHASE IN FIRST MONTHS IS FOLLOWED
BY RELATIVE STABILIZATION DURING DYNAMIC PHASE
    * Findings suggest that ND4-LHON patients matching the
RESCUE and
REVERSE populations have an acute need for therapeutic
intervention.

Source text for Eikon:  ID:nBw3FMk4ja 
Further company coverage:  SIGHT.PA 

 (Reporting by Sudip Kar-Gupta)
 ((sudip.kargupta@thomsonreuters.com;))